SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Update: AbbVie headquarters building in California
Earnings
AbbVie Trims Full-Year Earnings Guidance Due to R&D Milestone Costs
The company is lowering its previously issued guidance for 2024 adjusted earnings per share by $0.04 per share to account for acquired in-process research and development expenses incurred for acquisitions and collaborations in the third quarter.
October 4, 2024
 · 
1 min read
 · 
Tristan Manalac
Pictured: Office building science collage
Career Advice
The Top 12 Companies Hiring in Biopharma Now
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
October 3, 2024
 · 
1 min read
 · 
Angela Gabriel
AbbVie's office in South San Francisco, California
Parkinson’s disease
AbbVie’s $8.7B Cerevel Buy Starts to Pay off With Phase III Parkinson’s Win
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, will help AbbVie as it builds a regulatory case for the D1/D5 dopamine receptor agonist.
September 27, 2024
 · 
2 min read
 · 
Tristan Manalac
Mind health concept. Human face side view silhouette and alter ego
Schizophrenia
5 Schizophrenia Candidates Chasing BMS’ KarXT
As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the late-stage pipeline for this neuropsychiatric disorder.
September 23, 2024
 · 
6 min read
 · 
Heather McKenzie
Medical characters fighting the epidemic flat vector concept operation hand drawn illustration
Business
Lilly, Pfizer Take Meds Straight To Consumers in Renewed DTC Push
Big Pharma has finally gotten its arms around something advocates have wanted for a long time: direct-to-consumer sales. Eli Lilly and Pfizer are leading the way.
September 4, 2024
 · 
5 min read
 · 
Annalee Armstrong
An eye and DNA
Gene Therapy
Beyond Rare Disease: Wet AMD Gene Therapy Could Reach Millions
With gene therapies by REGENXBIO and AbbVie, Adverum and others in mid- or late-stage trials, this therapeutic class could soon be an option for this common cause of blindness in the elderly.
September 3, 2024
 · 
7 min read
 · 
Kate Goodwin
Stack of documents. Pile of waste documents earmarked for Recycling.
Patents
Patent Thickets in Federal Government’s Crosshairs as Election 2024 Looms
Congress, the Federal Trade Commission and the U.S. Patent and Trademark Office are all targeting Big Pharma’s practice of filing multiple, overlapping patents that stifle generic and biosimilar competition.
August 28, 2024
 · 
7 min read
 · 
Greg Slabodkin
Signage outside Express Scripts' headquarters in Missouri
Pharmacy benefit managers
Cigna to Remove AbbVie’s Humira From Formularies, Putting More Pressure on Blockbuster
Mirroring fellow pharmacy benefit manager CVS Caremark, Cigna’s Express Scripts is taking Humira off its major commercial formularies starting next year and focusing on more affordable biosimilar options.
August 27, 2024
 · 
2 min read
 · 
Tristan Manalac
AbbVie's office in South San Francisco, California
Approvals
AbbVie, Genmab Secure European Label Expansion for Tepkinly in Follicular Lymphoma
Two months after winning FDA approval in the same indication, AbbVie and Genmab on Monday secured the European Commission’s nod for its bispecific antibody Tepkinly for the most common type of low-grade non-Hodgkin lymphoma.
August 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Press Releases
AbbVie Reports Third-Quarter 2024 Financial Results
October 30, 2024
 · 
28 min read
Press Releases
AbbVie’s VRAYLAR® (cariprazine) Now Publicly Reimbursed in Ontario
October 29, 2024
 · 
3 min read
Press Releases
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer’s Disease and Neuroscience Pipeline
October 29, 2024
 · 
5 min read
News
AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions
October 24, 2024
 · 
10 min read
Press Releases
Nine Provinces Approve Accelerated Public Reimbursement of Diffuse Large B-Cell Lymphoma Treatment Under New Early Access Process
October 22, 2024
 · 
5 min read
Press Releases
BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
October 21, 2024
 · 
13 min read
Press Releases
U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson’s Disease
October 17, 2024
 · 
12 min read
Press Releases
Allergan Aesthetics to Present New Data at 2024 American Society for Dermatologic Surgery (ASDS) to Showcase Depth Across Facial Aesthetics and Insight into Patient Perception
October 17, 2024
 · 
7 min read
Press Releases
AbbVie to Host Third-Quarter 2024 Earnings Conference Call
October 1, 2024
 · 
1 min read
Press Releases
Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June
October 1, 2024
 · 
4 min read
Load More